During the trial, patients treated with Fabhalta experienced a significant reduction in proteinuria as early as two weeks.

The kidney damage from C3 glomerulopathy happens when your body’s complement system goes into overdrive. Here’s how it impacts your kidneys.

SAN DIEGO — The investigational drug pegcetacoplan, a C3/C3b inhibitor, showed significant benefits in the treatment of patients with C3 glomerulopathy or primary immune complex–mediated ...

A specialized low-salt fasting-mimicking diet revives kidney function in preclinical animal models and patients with chronic ...

A recent study has shown that the prevalence of glomerular damage in adults with various forms of sickle cell anemia is much higher than previously thought. Guasch and colleagues investigated the ...

Basel, October 27, 2024 – Novartis today presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3 ...

The results showed that patients with C3 glomerulopathy (C3G) treated with oral Fabhalta (iptacopan) alongside supportive care experienced clinically meaningful and sustained results over one year.

A study reveals that a low-salt fasting-mimicking diet slows kidney disease progression in animal models and shows protective ...

Complement 3 Glomerulopathy (C3G) an ultra-rare, progressive renal disorder primarily afflicting children and young adults. Caused by dysregulation of the alternative pathway of complement ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex ...

1 About C3 glomerulopathy (C3G) C3G is an ultra-rare, progressive kidney disease that initially presents mostly in children and young adults.3,4,9 Each year, approximately 1-2 people per ...